INTRODUCTION

Autism Spectrum Disorder (ASD) includes a group of developmental disabilities characterized by impaired social interaction and communication, among the presence of stereotyped behaviors and restricted interests [1]. In addition to these core symptoms, individuals with ASD often show a variety of additional impairments such as intellectual disability, epilepsy, motor deficits, hyperactivity, aggression, mood disorder, and sleep, sensory and gastrointestinal abnormalities [2]. Due to a lack of biological markers, the clinical diagnosis is solely based on behavioral observation and, being behavior a continuous domain, the final clinical phenotype among ASD patients can vary significantly. Although first thought to be mainly environmental and attributed to parental habits, today we know that ASD is largely genetic, however so far no major causative gene has been identified; rather studies have identified hundreds of risk genes, with either rare variants that are highly penetrant or common variants with small effect [3]. With this extraordinary genetic heterogeneity it is not surprising that no characteristic neuropathology has been conclusively identified for the disorder. However, the "many genes common pathways" hypothesis suggests that, although through different specific molecular mechanisms, the many genes associated with ASD will converge in their effect on the development and function of neural circuits involved in social cognition and language, core behaviors of autism [4]. The identification of these common neurobiological pathways will aid in the development of targeted therapies, which are currently absent in ASD. With an estimated prevalence of 1 in 68 individuals [5] the development of targeted effective drugs becomes a critical health issue. Despite the absence of targeted treatments, it is believed that as many as 75% of patients with ASD receive some kind of pharmacological treatment, which are mainly directed to treat non-core associated symptoms such as hyperactivity.

Key words: Autism, ASD, Pharmacotherapy, Treatment, Social behavior, Repetitive behavior

New Therapeutic Options for Autism Spectrum Disorder: Experimental Evidences

Olga Peñagarikano*
Department of Pharmacology, School of Medicine, University of the Basque Country, Sarriena s/n, Leioa 48940, Spain

Autism spectrum disorder (ASD) is characterized by impairment in two behavioral domains: social interaction/communication together with the presence of stereotyped behaviors and restricted interests. The heterogeneity in the phenotype among patients and the complex etiology of the disorder have long impeded the advancement of the development of successful pharmacotherapies. However, in the recent years, the integration of findings of multiple levels of research, from human genetics to mouse models, have made considerable progress towards the understanding of ASD pathophysiology, allowing the development of more effective targeted drug therapies. The present review discusses the current state of pharmacological research in ASD based on the emerging common pathophysiology signature.

Received October 21, 2015, Revised November 25, 2015, Accepted November 25, 2015

*To whom correspondence should be addressed.
TEL: 34-94-6015560, FAX: 34-94-6013400
e-mail: olga.penagarikano@ehu.eus

Copyright © Experimental Neurobiology 2015.
www.enjournal.org

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
irritability, aggression and self-injury [6]. Since there are no specific biological targets, drug prescription in ASD has been limited to testing compounds known to alleviate certain symptoms based on their approved use for other disorders, without necessarily understanding their neurobiological effect. As the underlying neurobiology of ASD is being discovered, targeted more efficient drug therapy is becoming possible. A comprehensive review of the emerging common neuropathology associated with ASD has been recently published [7]. The present review examines progress made in translation of the emerging signature of the neurobiology of ASD into more effective targeted therapies for the disorder.

NON-TARGETED TREATMENTS

In ASD, the co-occurrence of associated medical comorbidities is often the most preoccupying issue for families since it greatly affects their quality of life and makes behavioral interventions directed towards core social symptoms challenging. Among associated symptoms, aggression related behaviors (aggression, self injury, irritability) and hyperactivity/inattention are the most common and the ones receiving the most pharmacological attention (Table 1). In fact, in some cases improvements in social interaction have been observed as a secondary effect of an overall reduction in maladaptive behaviors and not a primary therapeutic effect of these medications. Also, it should be noted that, as there are no biomarkers for the disorder, improvement is based on evaluation of behavior by either a clinician or caregiver documenting severity and/or frequency of behavioral disturbances, being unbiased assessment sometimes challenging.

To date, the only drugs that are approved by the United States Food and Drug Administration (FDA) to treat symptoms in patients with autism are risperidone (approved in 2006) and aripiprazole (approved in 2009), both atypical antipsychotics used to treat irritability, hyperactivity and aggression. Although conventional (typical) antipsychotics, such as haloperidol, a potent dopamine antagonist, were first used to treat disruptive behaviors in patients with autism, severe side effects (dyskinesia and dystonia) were reported with long term treatments making them unsuitable in most cases [8]. Still, short term treatment with typical antipsychotics is commonly used in cases of severe aggressive bouts. The development of second generation (atypical) antipsychotic drugs allowed for a treatment of aggressive behavior with fewer and milder side effects. Most atypical antipsychotics act on the serotonin and dopamine systems and, in addition, have affinity for a wide range of other receptors including adrenergic, histaminergic and cholinergic [9]. This broad targeting of receptor systems is likely the cause of the variability in their efficiency and adverse effects associated to these drugs. Risperidone is the most widely used and has been shown to improve symptoms of irritability, aggression, hyperactivity, self-injury and stereotipies, although common side effects include weight gain, drowsiness and sedation, drooling, tremor, and dizziness [10, 11]. Aripiprazole is a newer atypical antipsychotic shown to improve irritability in patients with autism with usually milder side effects that involve weight gain, fatigue and somnolence, gastrointestinal symptoms and motor restlessness [12]. Other atypical antipsychotics such as clozapine and olanzapine have been used with limited benefits.

Stimulants commonly used to treat Attention Deficit and Hyperactivity Disorder (ADHD) have long been used to treat inattention, impulsivity and hyperactivity in patients with ASD.

| Class          | Action       | Drug   | Targeted symptoms      |
|----------------|--------------|--------|------------------------|
| Antipsychotics | Typical*     | Haloperidol | Aggression/irritability |
|                | Atypical**   | Risperidone | Aggression/irritability |
|                |              | Aripiprazole | Aggression/irritability |
| Stimulants     | DRI          | Methylphenidate | Hyperactivity/inattention |
| Antihypertensive | a2AR agonists | Guanfacine       | Hyperactivity/inattention |
|                |              | Clonidine       | Hyperactivity/inattention |
| Antidepressants | NRI          | Atomoxetine     | Hyperactivity/inattention |
|                | SSRI         | Fluoxetine      | Repetitive behavior/impulsivity |
|                |              | Citalopram     | Repetitive behavior/impulsivity |
| CNS depressant | MT receptors | Melatonin       | Sleep problems          |

*Typical: first generation antipsychotics, mainly act as dopamine D2 receptor antagonist.
**Atypical: second generation antipsychotics, mainly act as dopamine D2 and serotonin 2A receptors antagonists.
Abbreviations: DRI: dopamine reuptake inhibitor, SSRI: selective serotonin reuptake inhibitor, NRI: norepinephrine reuptake inhibitor, a2AR: Adrenergic alpha-2 receptor agonists, MT: melatonin.
According to the fifth edition of the American Psychiatric Association’s Diagnostic and Statistical Manual (DMS-V), ASD and ADHD are no longer mutually exclusive [1], therefore patients with autism no longer need to be treated off-label for ADHD symptoms. The psychostimulant methylphenidate is currently the most commonly used and has been shown to improve hyperactivity and inattention [13]. Other ADHD approved drugs such as the antidepressant atomoxetine, a norepinephrine reuptake inhibitor [14], and the antihypertensives guanfacine and clonidine, both α-2A adrenergic receptor agonists, have also shown moderate improvements in hyperactivity and inattention [15].

Other antidepressants, mostly selective serotonin reuptake inhibitors (SSRI), are widely used in the treatment of maladaptive behaviors in ASD. The most commonly used are fluoxetine and citalopram [16]. Initial evidence that they improved repetitive behaviors and compulsion generated the belief that these behaviors in ASD were similar to the ones observed in Obsessive Compulsive Disorder (OCD), since SSRIs are the standard treatment in OCD. However, consequent trials have shown a low level of effectiveness [17] and the presence of undesired side effects such as hyperactivity, agitation, insomnia, and aggression have been reported, raising questions about their suitability in the treatment of repetitive behaviors in ASD.

Sleep problems are reported in up to 55% of children with ASD [2], and it’s usually associated with worsening of behavioral symptoms. Melatonin related drugs are one of the most commonly used pharmacotherapies to aid in sleep function, ameliorating some of the associated behavioral problems in these patients [18].

In addition to the above described drugs, many other compounds such as anticonvulsants, cholinesterase inhibitors, opioid antagonists and others have been tested in patients with ASD with limited or low evidence of their benefits.

**ASD NEUROBIOLOGY: IN SEARCH FOR TARGETED TREATMENTS**

The integration of findings obtained through multiple levels of research, from human genetic studies to transcriptomic and neuropathological analyses of postmortem brain, has translated into considerable progress towards the understanding of ASD pathophysiology [7]. In addition, animal models based on human genetic findings have been key in the understanding of gene function as well as in the development and evaluation of the effectiveness of pharmacological treatments (Fig. 1). The traditional concept that abnormalities occurring during brain development are permanent and thus neurodevelopmental disorders irreversible, has been challenged in the past few years by studies on mouse models of neurodevelopmental disorders including Rett syndrome [19], fragile X syndrome [20], neurofibromatosis type 1 [21], Down’s syndrome [22], and tuberous sclerosis [23] when showing that brain activity and ultimately the associated cognitive and behavioral deficits can be restored in the mature brain. This has also been shown to be true for autism, where an increasing number of studies in mouse models have shown that certain behavioral and molecular defects can be reversed in the mature mouse brain, paving the way for clinical trials in human patients. Thus, if a dysfunction in a neurochemical signaling pathway is identified, targeted pharmacological therapies aiming to restore or compensate these imbalances could be effective. A summary of the published clinical trials for targeted treatments in ASD can be found in Table 2.

Experimental findings in mouse models are currently leading drug development towards the following emerging common affected neurobiological mechanisms in ASD: synaptic transmission and serotonin and oxytocin signaling.

**SYNAPTIC TRANSMISSION**

A large number of the genes identified as associated with ASD encode proteins involved in synaptic transmission [24]. Dendritic spines are the sites of most glutamatergic excitatory neurotransmission and their development, maturation and plasticity are critical for correct synapse function [25]. Alterations
in dendritic spines, including spine density, morphology and/or dynamics have been identified in postmortem studies of ASD patients, as well as in studies of animal models of autism [26]. Accordingly, drugs that enhance spine maturation represent a possible therapeutic option. One such medication is the insulin-like growth factor 1 (IGF-1), which regulates synapse formation. IGF-1 has been shown to promote the formation of mature excitatory synapses in neurons generated from induced pluripotent stem cells from patients with Phelan-McDermid syndrome (PMS), a complex neurodevelopmental disorder associated with ASD [27], as well as to reverse several phenotypes in the mouse model of the syndrome, deficient for Shank3 [28]. A pilot study of IGF-1 treatment in children with PMS recently showed significant improvement in social impairment and restrictive behaviors with no serious adverse effects reported [29]. The fact that synaptic transmission might represent a common pathophysiological pathway in ASD has led to the use of glutamatergic and GABAergic agents in preclinical models, with reasonable success. The most common genetic cause of autism, accounting for about 1% of cases, is Fragile X syndrome (FXS). FXS is caused by the absence of the protein encoded by the FMR1 gene (FMRP), an mRNA binding protein involved in protein synthesis through translational repression [30]. The mouse model of FXS, knockout for the Fmr1 gene, shows increased density in dendritic spines and altered spine morphology [31]. In addition, Fmr1-knockout mice show enhanced signaling through group I metabotropic glutamate receptor type 5 (mGluR5) [32]. Decreasing mGluR5 activity in this mouse model, by crossing it with mutant mice for mGluR5, rescued protein synthesis, dendritic spine alterations, and multiple behavioral phenotypes [20]. Since mGluR5 and the ionotropic glutamate receptor NMDA show a positive reciprocal regulation, where activation of either one of them potentiates the response mediated by the other one and, in a similar way, antagonism of either one of them indirectly inhibits the function of the other [33], modulators of both types of receptors constitute a promising pharmacotherapy in ASD. Memantine is an NMDA receptor antagonist approved by the FDA for use in other neurological disorders such as Alzheimer’s disease. Interestingly, memantine treatment in cultured cerebellar granule cells from Fmr1 knockout mice rescued dendritic spine density and maturation and restored the excitatory synapses to a normal range [34]. Several studies have investigated its effect in patients with autism with significant improvements reported in language and social behaviors [35, 36] as well as with a reduction in repetitive behaviors, hyperactivity and irritability when administered together with risperidone as adjunctive therapy [37]. Interestingly, Chung and collaborators [38] have recently shown that either NMDA antagonism through memantine or mGluR5 antagonism through MPEP rescues social deficits as well as NMDA hyperactivity shown in IRSp53 knockout mice, a gene linked to ASD in humans. Conversely, mice knockout for another autism susceptibility gene, Shank2, show decreased NMDA receptor function and treatment with either the NMDA agonist D-cycloserine or an mGluR5 positive allosteric modulator restores NMDA activity and social behavior [39]. In fact, a small pilot study in patients with autism has recently shown an improvement in social and repetitive behaviors after treatment with D-cycloserine [40-42].

As opposed to the mouse model of FXS, the mouse model of another syndromic form of ASD, Tuberous Sclerosis (TSC), presents with downregulation of mGluR5 signaling and, consequently, synaptic and cognitive defects in these mutants are corrected by treatments that modulate mGluR5 in opposite

Table 2. Clinical trials of targeted pharmacological treatments in ASD

| Class       | Drug      | Action                  | Results                                      | Ref.   |
|-------------|-----------|-------------------------|----------------------------------------------|--------|
| Growth factor | IGF-1    | IGF1 receptor          | Improved social behavior                     | [29]   |
|             |           |                         | Improved repetitive behavior                 | [29]   |
| Small molecule | Memantine | NMDAR antagonist       | Improved language                           | [34, 35] |
|             |           |                         | Improved social behavior                     | [34, 35] |
|             |           |                         | Reduced repetitive behavior                  | [36]*  |
|             |           |                         | Reduced hyperactivity                        | [36]   |
|             |           |                         | Reduced irritability                         | [36]   |
| Antibiotic  | D-cycloserine | NMDAR agonist         | Improved social behavior                     | [40, 41] |
| Small molecule | Arbaclofen | GABA(B)R agonist      | Improved social behavior                     | [54, 55] |
|             |           |                         | Reduced irritability                         | [55]   |
| Hormone     | Oxytocin  | OXT receptor           | Improved social behavior                     | [70-74] |

*When administered with risperidone as adjunctive therapy comparing with risperidone-only treatment.
Further research is needed to determine the safety and efficacy of these drugs in humans. A recent systematic

### SEROTONERGIC SYSTEM

Alterations in the functioning of the serotonin system were among the first biochemical changes found in individuals with ASD, with increased serotonin levels found in whole blood in up to 45% of patients [58] together with decreased serotonin receptor 5HT2A binding in hyperserotonemic individuals [59]. Variants in genes involved in the serotonin system, such as the serotonin transporter (SLC6A4) [60] and the monoamine oxidase A gene (MAOA) [61], involved in the degradation of serotonin, have been proposed as linked to ASD in humans. In support of this, mice with mutations in these genes present with abnormal serotonergic transmission and social deficits [62, 63]. The serotonin system is involved in many neurobiological processes, including brain development; therefore it is plausible that defects in this system would affect circuits important for ASD related behavior. Conversely, the most common serotonin related drugs used in ASD are SSRIs and, as described above, their effectiveness is not clear in most cases. It is possible that the variability in the response to SSRIs is due to a dysfunction of the serotonin system at different levels (receptor, transport, processing etc) [64] and thus, there is a potential for developing drugs affecting the serotonin system at more specific levels.

### OXYTOCIN

Perhaps the molecule that has received the most attention as a potential treatment for social deficits in ASD is the neuropeptide oxytocin (OXT). OXT is produced in the hypothalamus and is involved in the modulation of a broad range of social behaviors in mammals including maternal behavior, mother-infant bonding, pair bonding and social memory and recognition [65]. Animal studies have shown that in mice, OXT is required for the rewarding properties of social stimuli [66] and, accordingly, mice with a compromised OXT system, knockout for either the OXT gene, the OXT receptor gene, or a gene involved in OXT release (CD38), all show social deficits [67]. In humans, it has recently been shown that OXT plasma concentration and polymorphisms in the OXT receptor gene drive individual differences in social cognition in both ASD and normal populations [68]. Also, genetic variation in CD38 has recently been associated with a differential response in social eye cues in infants [69]. Therefore, variation in the OXT system seems to contribute to social phenotypes in humans, regardless of medical diagnosis. It is not surprising that a number of clinical trials have recently been conducted to test the efficacy of OXT treatment in the social domain of patients with autism, with very promising results [70-74]. A recent systematic
review of the published randomized controlled trials until 2013 reports that 85% of them found statistically significant differences in outcome related to social behavior between placebo and OXT treated groups, with eye gaze and facial emotion recognition being the domains more frequently improved [75]. In addition, some of these studies provide evidence of a neurobiological basis for improvement in social behavior through restoration of brain activity in specific areas. In particular, Aoki et al. [70] have recently shown that a single dose of intranasal OXT mitigated autistic behavioral deficits through the restoration of activity in the ventromedial prefrontal cortex, as demonstrated with functional magnetic resonance imaging (fMRI) during a socio-communication task. In addition, Watanabe et al. [71] have reported that a 6-week intranasal administration of OXT significantly improved social reciprocity in patients with ASD and fMRI showed that this improvement was accompanied by an OXT induced enhancement of resting-state functional connectivity between anterior cingulate cortex and dorso-medial prefrontal cortex. Therefore, there is a great interest in the investigation of OXT as a potential target for therapeutic treatment in ASD. A key issue is identifying which forms of ASD would benefit the most from OXT treatment, since detrimental effects could potentially occur by an overstimulation of this signaling pathway. There is evidence that some forms of ASD could potentially have an associated dysfunction in the OXT system. Genetic variation in the OXT receptor gene and CD38 has been linked to the disorder in some studies [76, 77]. Also, lower levels of peripheral OXT in patients with ASD have been found in some cohorts [78, 79], although higher levels have also been reported in other studies [80, 81]. In addition, Green and collaborators [82] found lower levels of the peptide but higher levels of its precursor, which suggests a dysfunction in its processing. This heterogeneity likely indicates dysfunction in the OXT system at different levels (i.e. synthesis, processing, storage, and release), adding to the challenge of developing a clinically useful biomarker. Research in genetic animal models are uncovering a potential dysfunction in the OXT system in some genetic forms of ASD, other than the directly related to the OXT system, which suggests that this could be a more extensive deficit than originally thought. For instance, the Fragile X mouse model, Fmr1 knockout, has been reported to show lower OXT immunoreactivity in the hypothalamus [83]. Interestingly, recent studies have reported improvement of social cognition in patients with Fragile X treated with intranasal OXT, and OXT is being considered as a potential treatment for social anxiety in this syndrome [84]. The Cntnap2 knockout mouse model of ASD, a gene involved in a syndromic form of ASD called Cortical Dysplasia and Focal Epilepsy syndrome [85] also shows lower OXT levels in brain, and both exogenous administration and activation of endogenous OXT release restored social behavior in this model [86]. Therefore, investigating potential impairments in the OXT system in other forms of ASD would be worthwhile. Animal models are also critical in helping understand the mechanism whereby OXT ejects its effects. OXT has been found to be involved in the perinatal excitatory to inhibitory shift of GABA during fetal and early postnatal periods [87], a process that is disrupted in the Fmr1 mouse model [88]. In the adult brain, OXT stimulates fast-spiking parvalbumin interneuron activity [89], therefore OXT could potentially compensate for GABAergic deficits found in these mouse models. Although research into the potential therapeutic application of OXT is still in the early stages, the OXT system is one of the most promising targets for improving social function. Possibly, analysis of OXT peripheral levels and OXT receptor sequence could become, to some degree, useful biomarkers to identify the most responsive individuals. In addition, OXT is known to interact with other neurotransmitter systems [67], a deeper understanding of the circuits involved will help develop therapeutic approaches based on manipulating this system.

In summary, despite the high heterogeneity in both the phenotype and the etiology of ASD, the integration of findings in recent studies at multiple levels of research have allowed a deeper understanding of ASD pathophysiology, identifying convergent mechanisms and allowing the development of more effective targeted drug therapies.

ACKNOWLEDGEMENTS

I would like to thank all colleagues that dedicate their work to studying the neurobiology and treatment of ASD, since they have contributed to a considerable progress in the field. OP is a Ramon y Cajal fellow and holds a NARSAD Young Investigator Grant.

REFERENCES

1. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Publishing, Washington DC.
2. Geschwind DH (2009) Advances in autism. Annu Rev Med 60:367-380.
3. Abrahams BS, Geschwind DH (2008) Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet 9:341-355.
4. Geschwind DH (2008) Autism: many genes, common pathways? Cell 135:391-395.
5. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC) (2014) Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 63:1-21.

6. Esbensen AJ, Greenberg JS, Seltzer MM, Aman MG (2009) A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. J Autism Dev Disord 39:1339-1349.

7. Chen JA, Peñagarikano O, Belgard TG, Swarup V, Geschwind DH (2015) The emerging picture of autism spectrum disorder: genetics and pathology. Annu Rev Pathol 10:111-144.

8. Mural S, Gencer O, Inal-Emiroglu FN, Baykara B, Baykara A, Dirik E (2008) Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 17:1-8.

9. Nasrallah HA (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13:27-35.

10. McQuade RD, Carson WH, Corey-Lisle PK, Aman MG (2011) Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol 21:229-236.

11. Hazell P (2007) Drug therapy for attention-deficit/ hyperactivity disorder-like symptoms in autistic disorder. J Paediatr Child Health 43:19-24.

12. Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, Ramadan Y (2006) Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 45:1196-1205.

13. Handen BL, Sahl R, Hardan AY (2008) Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr 29:303-308.

14. Williams K, Brignell A, Randall M, Silove N, Hazell P (2013) Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 8:CD004677.

15. King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, Hirtz D, Wagner A, Ritz L, Network SP, STAART Psychopharmacology Network (2009) Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 66:583-590.

16. Rossignol DA, Frye RE (2014) Melatonin in autism spectrum disorders. Curr Clin Pharmacol 9:326-334.

17. Hazell P, O’Connor T, Matthews C, Coon H, Arbuthnot A, Reason S, Heron P, Calzada J, Wapner K, Bakken ES, et al. (2012) Methylphenidate for children with autism spectrum disorder (ASD): a double-blind, double-dummy, placebo-controlled, randomized, parallel-group trial. J Am Acad Child Adolesc Psychiatry 51:690-698.

18. Berg JM, Geschwind DH (2012) Autism genetics: searching for specificity and convergence. Genome Biol 13:247.

19. Penzes P, Jones KA, van Leeuwen JE, Wulffrey KM (2011) Dendritic spine pathology in neuropsychiatric disorders. Nat Rev Neurosci 12:405-419.

20. Murch SH, Ring S, Wolstencroft K, Pinto D, Bussell D, Skuse D (2012) The effectiveness of interventions for children with autistic spectrum disorder: a systematic review. JAMA 307:1749-1760.
Dawson G, Duketis E, Fernandez BA, Gallagher L, Geller E, Guter SJ, Hill RS, Ionita-Laza J, Jimenez Gonzalez P, Kilpinen H, Klauck SM, Kolevzon A, Lee I, Lei I, Lei J, Lehtimäki T, Lin CF, Ma’ayan A, Marshall CR, McNnnes AL, Neale B, Owen MJ, Ozaki N, Parella M, Parr JR, Purcell S, Puura K, Rajagopalan D, Rehnström K, Reichenberg A, Sabo A, Sachse M, Sanders SJ, Schafer C, Schulte-Rüther M, Skuse D, Stevens C, Tammimies K, Valladares O, Voran A, Li-San W, Weiss LA, Williams AF, Yuen RK; DDD Study; Homozygosity Mapping Collaborative for Autism; UK10K Consortium, Cook EH, Freitag CM, Gill M, Hultman CM, Lehner T, Palotie A, Schellenberg GD, Sklar P, State MW, Sutcliffe JS, Walsh CA, Scherer SW, Zwick ME, Barett JC, Cutler DJ, Roeder K, Devlin B, Daly MJ, Buxbaum JD (2014) Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515:209-215.

27. Shcheglovitov A, Shcheglovitova O, Yazawa M, Portmann T, Shu R, Sebastiani V, Krawisz A, Froehlich W, Bernstein JA, Hallmayer JF, Dolmetsch RE (2013) SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature 503:267-271.

28. Bozdagi O, Tavassoli T, Buxbaum JD (2013) Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay. Mol Autism 4:9.

29. Kolevzon A, Bush L, Wang AT, Halpern D, Frank Y, Grossberg D, Rapaport R, Tavassoli T, Chaplin W, Soorya L, Buxbaum JD (2014) A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome. Mol Autism 5:54.

30. Penagarikano O, Mulle JG, Warren ST (2007) The pathophysiology of fragile X syndrome. Annu Rev Genomics Hum Genet 8:109-129.

31. Irwin SA, Galvez R, Greenough WT (2000) Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex 10:1038-1044.

32. Huber KM, Gallagher SM, Warren ST, Bear MF (2002) Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99:7746-7750.

33. Homayoun H, Stefani MR, Adams BW, Tamagan GD, Moghaddam B (2004) Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 29:1259-1269.

34. Wei H, Dobkin C, Sheikh AM, Malik M, Brown WT, Li X (2012) The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. PLoS One 7:e36981.

35. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C (2007) Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol 22:574-579.

36. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, Mc Dougle CJ (2007) A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) 191:141-147.

37. Ghaleiha A, Asadabadi M, Mohammad MR, Shaheki M, Tabrizi M, Hajighaee R, Hassanazadeh E, Akhondzadeh S (2013) Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 16:783-789.

38. Chung W, Choi SY, Lee E, Park H, Kang J, Park H, Choi Y, Lee D, Park SG, Kim R, Cho YS, Choi J, Kim MH, Lee J, Lee S, Rhiem I, Jung MW, Kim D, Bae YC, Kim E (2015) Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression. Nat Neurosci 18:435-443.

39. Won H, Lee HR, Gee HY, Mah W, Kim JI, Lee J, Ha S, Chung C, Jung ES, Cho YS, Park SG, Lee JS, Lee K, Kim D, Bae YC, Kang BK, Lee MG, Kim E (2012) Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486:261-265.

40. Posey DJ, Kem DL, Swiezy NB, Sweeten TL, Wiegand RE, McDougle CJ (2004) A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 161:2115-2117.

41. Urbano M, Okwara L, Manser P, Hartmann K, Herndon A, Deutsch SI (2014) A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder. Clin Neuropharmacol 37:69-72.

42. Urbano M, Okwara L, Manser P, Hartmann K, Deutsch SI (2015) A trial of d-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders. J Neuropsychiatry Clin Neurosci 27:133-138.

43. Auerbach BD, Osterweil EK, Bear MF (2011) Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480:63-68.

44. Ehninger D, Silva AJ (2011) Rapamycin for treating Tuberous...
sclerosis and Autism spectrum disorders. Trends Mol Med 17:78-87.
45. Gipson TT, Gerner G, Wilson MA, Blue ME, Johnston MV (2013) Potential for treatment of severe autism in tuberous sclerosis complex. World J Clin Pediatr 2:16-25.
46. Coghlan S, Horder J, Inkster B, Mendez MA, Murphy DG, Nutt DJ (2012) GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci Biobehav Rev 36:2044-2055.
47. Rubenstein JL, Merzenich MM (2003) Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2:255-267.
48. Yizhar O, Fenno LE, Prigge M, Schneider F, Davidson TJ, O'Shea DJ, Sohal VS, Goshen I, Finkelstein J, Paz JT, Stehfest K, Fudim R, Ramakrishnan C, Huguenard JR, Hegemann P, Deisseroth K (2011) Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 477:171-178.
49. Selby L, Zhang C, Sun QQ (2007) Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein. Neurosci Lett 412:227-232.
50. Peñagarikano O, Abrahams BS, Herman EI, Winden KD, Gdalyahu A, Dong H, Sonnenblick LI, Gruver R, Almajano J, Bragin A, Golshani P, Trachtenberg JT, Peles E, Geschwind DH (2011) Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell 147:235-246.
51. Sadakata T, Furuichi T (2009) Developmentally regulated Ca2+-dependent activator protein for secretion 2 (CAPS2) is involved in BDNF secretion and is associated with autism susceptibility. Cerebellum 8:312-322.
52. Sgadò P, Genovesi S, Kalinovsky A, Zunino G, Macchi F, Allegra M, Murenu E, Provenzano G, T ripathi PP, Casarosa S, Joyner AL, Bozzi Y (2013) Loss of GABAergic neurons in the hippocampus and cerebral cortex of Engrailed-2 null mutant mice: implications for autism spectrum disorders. Exp Neurol 247:496-505.
53. Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, Brynczka C, Rush R, Thomas A, Paylor R, Warren ST, Vanderklish PW, Kind PC, Carpenter RL, Bear MF, Healy AM (2012) Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med 4:152ra128.
54. Berry-Kravis EM, Hess D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez–Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ (2012) Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 4:152ra127.
55. Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scabill H, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King BH (2014) STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord 44:958-964.
56. Han S, Tai C, Westenbroek RE, Yu FH, Cheah CS, Potter GB, Rubenstein JL, Scheuer T, de la Iglesia HO, Catterall WA (2012) Autistic-like behaviour in Scn1a+/- mice and rescue by enhanced GABA-mediated neurotransmission. Nature 489:385-390.
57. Braat S, Kooy RF (2015) The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders. Neuron 86:1119-1130.
58. Cook EH Jr, Leventhal BL (1996) The serotonin system in autism. Curr Opin Pediatr 8:348-354.
59. Cook EH Jr, Arora RC, Anderson GM, Berry-Kravis EM, Yan SY, Yeoh HC, Sklena PJ, Charak DA, Leventhal BL (1993) Platelet serotonin studies in hyperserotonemic relatives of children with autistic disorder. Life Sci 52:2005-2015.
60. Conroy J, Meally E, Kearney G, Fitzgerald M, Gill M, Gallagher L (2004) Serotonin transporter gene and autism: a haplotype analysis in an Irish autistic population. Mol Psychiatry 9:587-593.
61. Cohen IL, Liu X, Schutz C, White BN, Jenkins EC, Brown WT, Holden JJ (2003) Association of autism severity with a monoamine oxidase A functional polymorphism. Clin Genet 64:190-197.
62. Lira A, Zhou M, Castanon N, Ansorge MS, Gordon JA, Francis JH, Bradley-Moore M, Lira J, Underwood MD, Arango V, Kung HF, Hofer MA, Hen R, Gingrich JA (2003) Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol Psychiatry 54:960-971.
63. Bortolato M, Godar SC, Alzghoul L, Zhang J, Darling RD, Simpson KL, Bini V, Chen K, Wellman CL, Lin RC, Shih JC (2013) Monoamine oxidase A and A/B knockout mice display autistic-like features. Int J Neuropsychopharmacol 16:869-888.
64. Muller CL, Anacker AM, Veenstra-VanderWeele J (2015) The serotonin system in autism spectrum disorder: From biomarker to animal models. Neuroscience. pii: S0306-4522(15)00999-9.
65. Ross HE, Young LJ (2009) Oxytocin and the neural
mechanisms regulating social cognition and affiliative behavior. Front Neuroendocrinol 30:534-547.
66. Dölen G, Darvishzadeh A, Huang KW, Malenka RC (2013) Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin. Nature 501:179-184.
67. Modi ME, Young LJ (2012) The oxytocin system in drug discovery for autism: animal models and novel therapeutic strategies. Horm Behav 61:340-350.
68. Parker KJ, Garner JP, Libove RA, Hyde SA, Hornbeak KB, Carson DS, Liao CP, Phillips JM, Hallmayer JF, Hardan AY (2014) Plasma oxytocin concentrations and OXTR polymorphisms predict social impairments in children with and without autism spectrum disorder. Proc Natl Acad Sci USA 111:12258-12263.
69. Krol KM, Monakhov M, Lai PS, Ebstein RP, Grossmann T (2015) Genetic variation in CD38 and breastfeeding experience interact to impact infants’ attention to social eye cues. Proceedings of the National Academy of Sciences of the United States of America.
70. Aoki Y, Yahata N, Watanabe T, Takano Y, Kawakubo Y, Kuwabara H, Iwawashi N, Natsubori T, Inoue H, Suga M, Takao H, Sasaki H, Gonoi W, Kunimitsu A, Kasai K, Yamasue H (2014) Oxytocin improves behavioural and neural deficits in inferring others’ social emotions in autism. Brain 137:3073-3086.
71. Watanabe T, Abe O, Kuwabara H, Yahata N, Takano Y, Iwawashi N, Natsubori T, Aoki Y, Takao H, Kawakubo Y, Kamio Y, Kato N, Miyashita Y, Kasai K, Yamasue H (2014) Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: a randomized trial. JAMA Psychiatry 71:166-175.
72. Althaus M, Groen Y, Wijers AA, Noltes H, Tucha O, Hoekstra PJ (2015) Oxytocin enhances orienting to social information in a selective group of high-functioning male adults with autism spectrum disorder. Neuropsychologia 79:53-69.
73. Aoki Y, Watanabe T, Abe O, Kuwabara H, Yahata N, Takano Y, Iwawashi N, Natsubori T, Aoki Y, Takao H, Kawakubo Y, Kasai K, Yamasue H (2015) Oxytocin’s neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: a randomized controlled trial. Mol Psychiatry 20:447-453.
74. Watanabe T, Kuroda M, Kuwabara H, Aoki Y, Iwawashi N, Tatsunobu N, Takao H, Nippashi Y, Kawakubo Y, Kunimitsu A, Kasai K, Yamasue H (2015) Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism. Brain 138:3400-3412.
75. Preti A, Melis M, Siddi S, Vellante M, Doneddu G, Fadda R (2014) Oxytocin and autism: a systematic review of randomized controlled trials. J Child Adolesc Psychopharmacol 24:54-68.
76. Lerer E, Levi S, Israel S, Yaari M, Nemanov L, Mankuta D, Nuriy, Ebstein RP (2010) Low CD38 expression in lymphoblastoid cells and haplotypes are both associated with autism in a family-based study. Autism Res 3:293-302.
77. LoParo D, Waldman ID (2015) The oxytocin receptor gene (OXTR) is associated with autism spectrum disorder: a meta-analysis. Mol Psychiatry 20:640-646.
78. Modahl C, Green L, Fein D, Morris M, Waterhouse L, Feinstein C, Levin H (1998) Plasma oxytocin levels in autistic children. Biol Psychiatry 43:270-277.
79. Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M, Sirigu A (2010) Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci USA 107:4389-4394.
80. Jansen LM, Gispen-de Wied CC, Wiegant VM, Westenberg HG, Lahuis BE, van Engeland H (2006) Autonomic and neuroendocrine responses to a psychosocial stressor in adults with autistic spectrum disorder. J Autism Dev Disord 36:891-899.
81. Jacobson JD, Ellerbeck KA, Kelly KA, Fleming KK, Jamison TR, Coffey CW, Smith CM, Reese RM, Sands SA (2014) Evidence for alterations in stimulatory G proteins and oxytocin levels in children with autism. Psychoneuroendocrinology 40:159-169.
82. Green L, Fein D, Modahl C, Feinstein C, Waterhouse L, Morris M (2001) Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry 50:609-613.
83. Francis SM, Sagar A, Levin-Decanini T, Liu W, Carter CS, Jacob S (2014) Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders. Brain Res 1580:199-218.
84. Hall SS, Lightbody AA, McCarthy BE, Parker KJ, Reiss AL (2012) Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology 37:509-518.
85. Strauss KA, Puffenberger EG, Huentelman MJ, Gottlieb S, Dobrin SE, Parod JM, Stephan DA, Morton DH (2006) Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med 354:1370-1377.
86. Peñagarikano O, Lázaro MT, Lu XH, Gordon A, Dong H, Lam HA, Peles E, Maidment NT, Murphy NP, Yang XW, Golshani P, Geschwind DH (2015) Exogenous and evoked oxytocin restores social behavior in the Cntnap2 mouse model of autism. Sci Transl Med 7:271ra8.
87. Tyzio R, Cossart R, Khalilov I, Minlebaev M, Hubner CA, Represa A, Ben-Ari Y, Khazipov R (2006) Maternal oxytocin triggers a transient inhibitory switch in GABA signaling in the fetal brain during delivery. Science 314:1788-1792.

88. Tyzio R, Nardou R, Ferrari DC, Tsintsadze T, Shahrokhi A, Eftekhari S, Khalilov I, Tsintsadze V, Brouchoud C, Chazal G, Lemonnier E, Lozovaya N, Burnashev N, Ben-Ari Y (2014) Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. Science 343:675-679.

89. Owen SF, Tuncdemir SN, Bader PL, Tirko NN, Fishell G, Tsien RW (2013) Oxytocin enhances hippocampal spike transmission by modulating fast-spiking interneurons. Nature 500:458-462.